The company will use the funds to progress the development of a non-opioid therapy for post-surgery pain management. Credit: Roman Zaiets / Shutterstock.com.

AmacaThera has secured C$4m ($2.94m) in a Series A extension funding round to progress the development of a non-opioid therapy, AMT-143, for post-surgery pain management.

New investor Paul Austin led the financing round with participation from current investors Inveready, Lumira Ventures, MaRS IAF, StandUp Ventures and the Women in Technology Venture Fund of BDC Capital. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

AmacaThera will use the funding capital to advance the clinical development of its lead candidate, AMT-143, a long-acting, localised therapeutic.

The company will also progress the development of pipeline programmes for the injectable, local and sustained release market.

AMT-143 has been developed using the company’s AmacaGel platform technology. It potentially offers a longer duration of pain relief following surgical procedures and reduces opioid use during recovery. 

Pre-clinical research showed that AMT-143 offers superior release kinetics versus the existing standard of care, resulting in quick pain relief onset with durable pain control for up to three days.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company dosed the first subjects in a Phase I first-in-human clinical trial to ascertain the safety of AmacaGel in March 2023.

A Phase Ib clinical trial of the therapeutic will begin in early 2024.

AmacaThera CEO and co-founder Dr Michael Cooke stated: “We are excited to welcome our new lead investor to our board, as they share our enthusiasm for AmacaThera’s vision and potential for long-term success.

​“This investment will enable us to expand and accelerate our efforts in developing new long-acting injectable products.”

The clinical-stage company’s AmacaGel injectable hydrogel platform offers local, sustained drug delivery to boost outcomes in patients across treatment fields including post-surgical pain management, cancer and unmet medical needs. 

Paul Austin stated: ​“AmacaThera is developing a product that fulfils both societal and medical needs for a large market.”